Binders

Information

  • Patent Grant
  • 11060276
  • Patent Number
    11,060,276
  • Date Filed
    Wednesday, May 31, 2017
    6 years ago
  • Date Issued
    Tuesday, July 13, 2021
    2 years ago
Abstract
The invention relates to an aqueous binder composition comprising a carbohydrate component, possibly a crosslinker and possibly reaction product of carbohydrate component with crosslinker, further comprising a phenalkamine. The invention further discloses binders obtained therefrom and composite products manufactured therewith.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a U.S. national counterpart application of International Application Serial No. PCT/EP2017/063147, filed May 31, 2017, under 35 U.S.C. § 371, which claims priority to GB Application Serial No. 1610063.8, filed Jun. 9, 2016, the disclosures of which are hereby incorporated herein by reference.


The present invention relates to composite products manufactured using a binder composition which comprises a carbohydrate component, possibly a crosslinker, possibly reaction product of carbohydrate component and crosslinker; it also relates to such binders obtained from said binder composition.


While known carbohydrate based binders and composite material made therewith show interesting mechanical properties, there always is a need to further improve said properties, more specifically under humid or wet conditions.


In accordance with one of its aspects, the present invention provides a binder composition as defined in claim 1. Further aspects are defined in other independent claims. The dependent claims define preferred or alternative embodiments.


The term “binder composition” as used herein means all ingredients applied to the matter to be bound and/or present on the matter to be bound, notably prior to curing, (other than the matter and any moisture contained within the matter) including reactants, solvents (including water), any carbohydrate component, any crosslinker and any additives.


The term “binder” is used herein to designate a thermoset binder resin obtained from the “binder composition”.


The term “cured” means that the components of the binder composition have been subjected to conditions that lead to chemical change, such as covalent bonding, hydrogen bonding and chemical crosslinking, which may increase the cured product's durability and solvent resistance, and result in thermoset material.


The term “dry weight of the binder composition” as used herein means the weight of all components of the binder composition other than any water that is present (whether in the form of liquid water or in the form of water of crystallization).


The term “carbohydrate component” as used herein means a carbohydrate or derivative thereof, including monosaccharides, disaccharides, oligosaccharides and polysaccharides. Examples are glucose, fructose, xylose, sucrose, maltose, trehalose, sorbitol, dextrines, maltodextrins, amylose, amylopectine, starch, modified starches, cellulose, hemicellulose, and pectins, hydrolysis products thereof, precursors thereof that form the relevant carbohydrates or derivatives thereof in situ, and mixtures thereof. The carbohydrate component may be a reducing sugar reactant or a non-reducing sugar that generates a reducing sugar in situ.


The term “crosslinker” as used herein comprises compounds that are capable of reacting with the carbohydrate component to form ramifications or reticulations of the said carbohydrate component.


Phenalkamines are known as curing agents and may be obtained by the reaction of an alkylphenol with aliphatic polyamines and formaldehyde. The polyamine advantageously is an amine having two or more primary amine functionalities, possibly substituted with additional secondary amine functionalities.


A preferred phenalkamine shows the general formula below




embedded image



wherein


R1 is a straight or branched, saturated or unsaturated alkyl group comprising 12 to 24 C-atoms


R2 and R3 are linear or branched alkanediyl having 2 to 20 C-atoms, cycloaliphatic groups or contain aromatic groups and


x is an integer ranging from 0 to 5 and y is an integer ranging from 1 to 5.


Suitable polyamines for reaction with alkylphenol and formaldehyde show the general formula

H2N—((—R2—NH—)x—R3—)y—NH2

wherein R2 and R3 are linear or branched alkanediyl having 2 to 20 C-atoms, cycloaliphatic groups or contain aromatic groups, and x is an integer ranging from 0 to 5 and y is an integer ranging from 1 to 5.


Examples of polyamines include, but are not limited to: ethyleneamines such as 1,2-ethanediamine (EDA), N-(2-aminoethyl)-1,2-ethanediamine (DETA), N,N-bis(2-amino-ethyl)-I,2-ethanediamine (TETA), N-(2-aminoethyl)-N′-[(2-amino-ethyl)amino-ethyl]-I,2-ethanediamine (TEPA), aminoethylpiperazine, and higher polyethylenepolyamines, 1,3-benzenedimethanamine (MXDA—metaxylylene diamine); 1,3-cyclohexanedimethanamine (1,3-BAC); 1,2-diaminocyclohexane (DACH); norbornanediamine; isophorone diamine; 5-amino-I,3,3-trimethylcyclo-hexanemethanamine (IPDA); trimethylhexamethylenediamine (TMD); 1,3-pentanediamine; 2-methyl-I,5-pentanediamine; 1,6-hexanediamine (HMDA) and 4,4′-diaminodicyclohexylmethane (PACM).


The binder composition may be used in the manufacturing of composite products, such as wood boards, for example wood particle boards, medium density fibreboard (MDF), chip boards or orientated strand board (OSB), and plywood. The binder may be used to bond abrasive particles together and/or onto a backing sheet or to bond fibers, such as woven and non-woven natural, synthetic, textile or mineral fibers, for instance glass fibers or mineral wool fibers. Such bonded mineral fibers, for instance mineral glass wool or stone wool fibers, may be used in the manufacturing of thermal and/or acoustic insulating materials.


A wood particle board is a composite material manufactured from wood particles, for example wood chips, sawmill shavings and/or saw dust at varying particle sizes held together by a binder and used especially for the manufacture of furniture, such as cabinets, kitchens and bathroom furniture. Generally, wood particle board (which is sometimes referred to as “chipboard”) is produced by mixing wood particles and a binder composition, e.g. a thermo-curable resin, subsequently forming the resulting mixture into a sheet or mat and compressing said sheet or mat under elevated temperatures.


Plywood is a composite sheet material manufactured from thin layers of wood glued together by a binder, adjacent wood layers having their wood grain rotated by approx. 90 degrees to one another.


When used as a binder in wood boards, such as plywood, particle boards, fiber boards, the solid content of the aqueous binder composition may range from 50 to 95 w %, preferably 50 to 90 w %, more preferably 55 to 85 w % or even 60 to 80 w %, based upon the weight of the total aqueous binder composition.


The binder may also be used to bond synthetic or natural fibers, for instance mineral fibers, such as glass fibers, glass wool or stone wool. In view of the manufacture of a fiber mat, such as for insulating products, for instance, an aqueous binder composition is applied onto the fibers, e.g. by spraying, and the binder impregnated mineral fibers are deposited as a mat and subsequently subjected to heat for curing of the binder composition, hence forming an assembly of bonded fibers.


When used in the manufacture of a fiber based composite, the solid content of the invention aqueous binder composition may range from 5 to 95 w %, advantageously from 8 to 90 w %, preferably from 10 to 85 w %, based on the weight of the total aqueous binder composition. More specifically, when used as a binder for mineral wool insulation, the solid content of the aqueous binder composition may be in the range from 5 to 25 w %, preferably from 8 to 20 w %, more preferably from 10 to 20 w % or even 12 to 18 w %, based on the weight of the total aqueous binder composition.


In preferred embodiments, the present invention provides improved product and/or binder performance, notably mechanical performance, under wet or humid conditions. This makes the binders particularly suitable where sensitivity to water or humidity is an important criteria, for example wood boards.


It has been found that the phenalkamine component reacts with the carbohydrate component and/or the cross-linker and confers water-resistance properties to the binder through its hydrophobic groups, and hence to the composite product incorporating said binder. As a result, the binder composition of the invention may be used to form a water-resistant silicone-free binder and composite incorporating said binder.


The crosslinker may advantageously be selected from mono- or polycarboxylic acids, including monomeric and polymeric polycarboxylic acids, such as polyacrylates, and nitrogenous components. The nitrogenous component may be selected from NH3, an inorganic amine or an organic amine comprising at least one primary amine group, as well as salts thereof. It may comprise NH3 used as such (e.g. in form of an aqueous solution), or an inorganic or organic ammonium salt, for example ammonium sulfate (AmSO4), ammonium phosphate, e.g. diammonium phosphate, ammonium chloride, ammonium nitrate or ammonium citrate. The nitrogenous component may also be a polyamine, that is any organic compound having two or more amine groups, which may independently be substituted or unsubstituted. For example, the polyamine may be a primary polyamine. As used herein, a “primary polyamine” is an organic compound having two or more primary amine groups (—NH2). Within the scope of the term primary polyamine are those compounds which can be modified in situ or isomerize to generate a compound having two or more primary amine groups (—NH2). The primary polyamine may be a molecule having the formula H2N-Q-NH2, wherein Q is an alkanediyl, cycloalkanediyl, heteroalkanediyl, or cycloheteroalkanediyl, each of which may be optionally substituted. For example, Q may be an alkanediyl group selected from —C2-C24—, an alkanediyl group selected from —C2-C9—, or an alkanediyl group selected from —C3-C7—. According to a preferred embodiment, Q is a C6 alkanediyl. According to another embodiment, Q may be a cyclohexanediyl, cyclopentanediyl or cyclobutanediyl, or a divalent benzyl radical. In this context, it should be noted that certain authors prefer using the term “alkyl” instead of the chemically more correct “alkanediyl” nomenclature; the same chemical group is meant. As used herein, the term “alkanediyl” means a chain of carbon atoms, which may optionally be branched, preferably of limited length, including —C1-C24—, —C1-C12—, —C1-C8—, —C1-C6—, and —C1-C4—. Shorter alkanediyl groups may add less lipophilicity to the compound and accordingly will have different reactivity towards the reducing sugar reactant and/or solubility.


As used herein, the term “cycloalkanediyl” means a chain of carbon atoms, which may optionally be branched, where at least a portion of the chain is cyclic and also includes polycyclic structures, for example, cyclopropanediyl, cyclopentanediyl, cyclohexanediyl, 2-methylcyclopropanediyl, 2-ethylcyclopentanediyl, adamantanediyl. Furthermore, the chain forming cycloalkanediyl is advantageously of limited length, including —C3-C24—, —C3-C12—, —C3-C8—, —C3-C6—, and —C5-C6—. Shorter alkanediyl chains forming cycloalkanediyl may add less lipophilicity to the compound and accordingly will have a different behaviour.


As used herein, the term “heteroalkanediyl” means a chain of atoms that includes both carbon and at least one heteroatom, and is optionally branched. Examples of such heteroatoms include nitrogen, oxygen, and sulfur. In certain variations, said hetero-atoms also include phosphorus, and selenium. In one embodiment, the heteroalkanediyl is a polyether. As used herein, the term “cycloheteroalkanediyl”, includes a chain of atoms that includes both carbon and at least one heteroatom, such as heteroalkanediyl, and may optionally be branched, where at least a portion of the chain is cyclic. Particularly, examples of cycloheteroalkanediyl include divalent tetrahydrofuryl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, morpholinyl, piperazinyl, homopiperazinyl, quinuclidinyl.


“Optionally substituted” means the replacement of one or more hydrogen atoms with other functional groups. Such other functional groups may include amino, hydroxyl, halo, thiol, alkyl, haloalkyl, heteroalkyl, aryl, arylalkyl, arylheteroalkyl, nitro, sulfonic acids and derivatives thereof, carboxylic acids and derivatives thereof.


The primary polyamine may be a diamine, triamine, tetramine, or pentamine, for example: a triamine selected from a diethylenetriamine, 1-piperazineethanamine, or bis(hexamethylene)triamine; triethylenetetramine; or tetraethylenepentamine. One feature of the primary polyamine is that it may possess low steric hindrance. For example, 1,2-diaminoethane, 1,4-diaminobutane, 1,5-diaminopentane, 1,6-diaminohexane, 1,12-diaminododecane, 1,4-diaminocyclohexane, 1,4-diaminobenzene, diethylenetriamine, triethylenetetramine, tetraethylenepentamine, 1-piperazine-ethanamine, 2-methyl-pentamethylenediamine, 1,3-pentanediamine, and bis(hexamethylene)triamine, as well as 1,8-diaminooctane have low steric hindrance.


Preferably, the nitrogenous component comprises or consists of 1,6-diaminohexane (hexamethylenediamine, HMDA) or 1,5-diamino-2-methylpentane (2-methyl-pentamethylenediamine.


In another embodiment, the nitrogenous component comprises or consists of a polyether-polyamine, which may be a diamine or a triamine, for example a trifunctional primary amine having an average molecular weight of 440 known as Jeffamine T-403 Polyetheramine (e.g. Huntsman Corporation). In yet another embodiment, the nitrogenous component may comprise or consist of a polymeric polyamine, for example chitosan, polylysine, polyethylene imine, poly(N-vinyl-N-methyl amine), polyaminostyrene, polyvinyl amine (which can be a homopolymer or a copolymer). Proteins, such as whey protein or soy protein, may also be used.


The binder composition may comprise a binder composition as described in any of WO 2007/014236, WO 2009/019232, WO 2009/019235, WO 2011/138458, WO 2011/138459 or WO 2013/150123, each of which is hereby incorporated by reference.


In the binder composition, the carbohydrate component is advantageously present in an amount ranging from 30%, preferably from 40%, preferably from 50%, more preferably from 60%, more preferably from 70%, even more preferably from 80% by dry weight of the binder composition, to less than 97% more preferably less than 95% by dry weight of the binder composition.


The crosslinker may make up:


less than 50% or 40%, preferably less than 30%, more preferably less than 25% by dry weight of the binder composition; and/or


at least 2.5%, preferably at least 5%, more preferably at least 10% by dry weight of the binder composition.


The binder composition may comprise at least 25%, and preferably at least 40%, at least 50% or at least 60% by dry weight of: (a) carbohydrate component and crosslinker and/or (b) curable reaction product(s) of carbohydrate component and crosslinker.


When the carbohydrate is a reducing sugar and the crosslinker is an amino compound, the ratio of carbonyl groups in the reducing sugar reactant(s) to reactive amino groups in the nitrogen-containing reactant(s) may be in the range of 5:1 to 1:2. For example, the ratio of carbonyl groups to reactive amino groups may be in the range of 5:1 to 1:1.8, 5:1 to 1:1.5, 5:1 to 1:1.2, 5:1 to 1:1, 5:1 to 1:0.8 and 5:1 to 1:0.5. Further examples include ratios such as 4:1 to 1:2, 3.5:1 to 1:2, 3:1 to 1:2, 2.5:1 to 1:2, 2:1 to 1:2 and 1.5:1 to 1:2. In this context, the term “reactive amino group” means any amino group in the crosslinker which is capable of reacting with the carbohydrate component. Specifically, examples of such reactive amino groups include primary and secondary amino groups, amide groups, imine and imide groups, as well as cyanate and isocyanate.


The crosslinker and the reducing sugar reactant(s) (or their reaction product(s)) may be Maillard reactants that react to form Maillard reaction products, notably melanoidins when cured. Curing of the binder composition may comprise or consist essentially of Maillard reaction(s). The cured binder is preferably a thermoset binder and is preferably substantially water insoluble.


The reducing sugar reactant may comprise: a monosaccharide, a monosaccharide in its aldose or ketose form, a disaccharide, a polysaccharide, a triose, a tetrose, a pentose, xylose, an hexose, dextrose, fructose, a heptose, a sugar, molasses, starch, starch hydrolysate, cellulose hydrolysates, reaction product(s) thereof or mixtures thereof as well as non-reducing sugars and derivatives thereof that generate a reducing sugar in situ, like sucrose or molasses. The reducing sugar reactant(s), or carbohydrate reactant(s) that yield the reducing sugar reactant(s) may have a dextrose equivalent of at least about 50, at least about 60, at least about 70, at least about 80 or at least about 90. The reducing sugar reactant may comprise or consist of high fructose corn syrup (HFCS).


The binder composition may comprise one or more adjuvants, for example waxes, dyes, dedusters, release agents and formaldehyde scavengers (notably urea, tannins, quebracho extract, ammonium phosphate bisulfite). It may further comprise, if so desired, appropriate catalysts that catalyse the reaction between carbohydrate component and crosslinker. Such catalysts may be selected from known catalysts, such phosphorous containing salts or acids. Examples are sodium hypophosphite, phosphates etc.


The binder composition is preferably free of, or comprises no more than 5 wt % or no more than 10 wt % urea formaldehyde (UF), melamine urea formaldehyde (MUF) and/or phenol formaldehyde.


The binder composition preferably does not comprise any added formaldehyde. It may be “substantially formaldehyde free”, that is to say that it liberates less than 5 ppm formaldehyde as a result of drying and/or curing (or appropriate tests simulating drying and/or curing); more preferably it is “formaldehyde free”, that is to say that it liberates less than 1 ppm formaldehyde in such conditions.


The binder composition of the invention may be applied to wood particles, abrasive particles, sheet material, or fibers, which may then be subjected to heat and/or pressure to cure the components of the binder composition in order to form a cured thermoset binder resin which holds the particles, sheet or fibers together in a composite material.


The binders of the invention may be used to bond a collection of non or loosely assembled matter. The collection of matter includes any collection of matter which comprises fibers selected from mineral fibers, slag wool fibers, stone wool fibers, glass fibers, aramid fibers, ceramic fibers, metal fibers, carbon fibers, polyimide fibers, polyester fibers, rayon fibers, and cellulosic fibers. Further examples of collection of matter include particulates such as coal, sand, cellulosic fibers, wood shavings, saw dust, wood pulp, ground wood, wood chips, wood strands, wood layers, other natural fibers, such as jute, flax, hemp, straw, wood veneers, facings and other particles, woven or non-woven materials. According to a specific embodiment of the invention, the collection of matter is selected from wood particles and mineral fibers.


In one illustrative embodiment, the binder composition of the invention may be used to make thermal insulation products, comprising mineral fibers. In such an application, the fibers are bonded together such that they become organized in a fiberglass mat which may then be processed into an insulation product. In such an application, the fibers are generally present in an amount ranging from 70 to 99% by total weight of the insulation product, notably from 80 to 99% or from 85 to 99%.


According to another embodiment of the invention, the binder may be used to bond cellulosic particles, such as cellulosic fibers, wood shavings, wood pulp and other materials commonly used to manufacture composite wood boards, including fiber boards, particle boards, oriented strand boards, plywood etc. Such wood boards show nominal thicknesses ranging from 6 to 30 mm and a modulus of Elasticity of at least about 1000 N/mm2, bending strength of at least about 5 N/mm2 and/or an internal bond strength of at least 0.10 N/mm2. In such applications, the binder content in the final wood board may range from about 5 to 30% wt with respect to the total weight of the wood board notably from 9 to 20%.


The aqueous binder composition may be applied onto the fiber or particulate material by spray application. Other possible techniques include roll application or mixing and/or tumbling the collection of matter with the binder composition. As water evaporates the binder composition may form a gel that bonds the particulate material together when arranged into a desirable assembly. When curing, the polyphenolic macromolecular compound and the polyamine functional compound are caused to react to form an essentially water insoluble macromolecular binder. Curing thus imparts increased adhesion, durability and water resistance as compared to uncured binder. Curing may be effected at temperatures between ambient and up to 280° C.





The invention will be described here below with reference to examples and Figures.


In the Figures:



FIG. 1 shows water absorption data for various binder compositions;



FIG. 2 shows an interval plot of strength diagram for various binder compositions;



FIG. 3 shows water absorption data for an invention composition compared to a known composition; and



FIG. 4 shows water absorption data for an invention binder composition compared to a binder composition comprising a silicone water repellent.





As mentioned earlier, the phenalkamine component appears to confer water-resistance properties to the binder incorporating it and to composite materials made with the invention binder. The advantageous properties of invention binder compositions and composite materials will be shown in more details herein below.


EXAMPLE 1

Glucose and ammonium sulphate were dissolved in water individually and combined at ambient temperature under stirring such as to obtain a glucose:ammonium sulphate ratio of 85:15 wt %, based on dry weight. A fraction of the obtained composition was retained as control (control 1). Another fraction was withdrawn and 3 wt % of polydimethylsiloxane based water repellent (Basildon Chemicals BC2631 which is a co-emulsion of blended reactive polydimethylsiloxanes for use on glass wool and mineral substrates) were added (based on dry weight) to form control 2. A further fraction of the initial binder composition was withdrawn and 3 wt % phenalkamine (RAC950 supplied by Royce International) were added as a 10% dispersion in water (B1). To a further fraction, 1.5 wt % BC2631 and 1.5 wt % RAC950 as a 10% aqueous dispersion were added (B2).


The binder compositions were applied onto a glass microfiber Whatman GF/A filter as follows: the glass filter was completely submerged for 5 seconds into a binder composition, fixed with a wire. The glass filter was then withdrawn and suspended in a frame placed in a drying oven at 200° C. for 10 min. After curing, the filter was weighted. The obtained composite product (bonded glass filter) was placed into a 400 ml beaker and 200 ml water were added. A glass rod was placed on top of the filter and the filter was left submerged in water for 1 hour. After 1 hour, the filter was withdrawn and water allowed to drip for 2 minutes. Excess water was removed using absorbent paper. The filter was weighted again. Water absorption (%) is calculated as 100×(mass wet filter−mass dry filter)/mass dry filter. The test results are summarized in FIG. 1.


As can be seen, and as expected, the addition of siloxane based water-repellent additive significantly reduces water uptake (compare control 1 and control 2). The addition of phenalkamine even further reduces water uptake (compare B1 and control 1). The combination of silicon based water repellent and phenalkamine performs similarly to the sole phenalkamine additive (see B2).


The compositions Control 1 and B1 were subjected to dry and wet tensile strength tests as follows: suitable strips of impregnated and cured glass veils were placed onto a testometric machine (M350-10CT) and tested using a 50 kg load cell at an automated test speed of 10 mm/min controlled by winTest Analysis software. Various parameters such as maximum load at peak, stress at peak and modulus (stiffness) were evaluated by the software, and data presented as an average of 8 samples with standard deviation. The average maximum load at peak or stress at peak defined as the bond strength. For the wet test, the cured veil samples were placed in an autoclave (J8341, Vessel: PV02626 with associated safety valve, door interlock and integrated pipework) system. Samples were treated at 90% humidity and at a temperature ranging from 40° C. to 110° C. (full cycle), at a pressure of up to 2.62 bar, for 3 hours. The samples were dried completely in order to ensure no moisture remains onto the veils. The autoclave treated samples were tested for bond strength by means of testometric machine (M350-10CT) described here above, and the results were compared with those of untreated samples. The test results are summarized in FIG. 2. The addition of phenalkamine does not significantly impact the tensile strength.


EXAMPLE 2

The same experiment was repeated with a binder composition comprising glucose and HMDA (hexamethylenediamine) in 85/15 ratio (B4) and a binder composition comprising glucose and HMDA (hexamethylenediamine) in 85/15 ratio plus 3 wt % phenalkamine (RAC950) added (B5) as a 10% aqueous dispersion. The results are shown in FIG. 3.


EXAMPLE 3

Example 1 was repeated with a binder composition comprising glucose and ammonium sulphate in a ratio of 85:15 wt %, based on dry weight. A fraction of the obtained composition was retained as control. Another fraction was withdrawn and 1 wt % of polydimethylsiloxane based water repellent (Basildon Chemicals BC2631 which is a co-emulsion of blended reactive polydimethylsiloxanes for use on glass wool and mineral substrates) were added (based on dry weight) to form a second control. A further fraction of the initial binder composition was withdrawn and 0.5 wt % phenalkamine (RAC950 supplied by Royce International) were added as a 10% dispersion in water together with 0.5 wt % of the above polydimethylsiloxane.


The water pick-up results are shown in FIG. 4. Clearly, the combination of silicone based water repellent and phenalkamine show improved water pick-up characteristics as compared to just silicone water repellent.

Claims
  • 1. An aqueous binder composition comprising a carbohydrate component, optionally comprising a crosslinker and optionally comprising a reaction product of the carbohydrate component and the crosslinker, wherein the aqueous binder composition further comprises a phenalkamine comprising the general formula
  • 2. The aqueous binder composition of claim 1, wherein R1 is C15H(31−n) wherein n is 0, 2, 4, or 6.
  • 3. The aqueous binder composition of claim 1, wherein R2 and R3 are each ethanediyl and x and y are each 1, or a phenalkamine of the general formula of claim 1 wherein R3 is ethanediyl, x is 0 and y is 1.
  • 4. The aqueous binder composition of claim 1, wherein the phenalkamine comprises 0.5-30 wt. %, based on the dry weight of the aqueous binder composition, optionally in combination with a silicone or silane comprising water repellent.
  • 5. The aqueous binder composition of claim 1, wherein the carbohydrate component is selected from the group consisting of monosaccharides, disaccharides, oligosaccharides polysaccharides, in situ precursors thereof and mixtures thereof.
  • 6. The aqueous binder composition of claim 1, wherein the crosslinker is selected from a polycarboxylic acid, salt, ester and/or anhydride derivatives thereof, and/or a nitrogenous component.
  • 7. The aqueous binder composition of claim 6, wherein the crosslinker comprises an ammonium salt of an inorganic acid or of a carboxylic acid, or a polyamine having at least two primary amine functionalities.
  • 8. The aqueous binder composition of claim 1, wherein the carbohydrate component comprises a concentration ranging from 30 wt. % by dry weight of the aqueous binder composition to less than 97 wt. % by dry weight of the aqueous binder composition.
  • 9. The aqueous binder composition of claim 1, wherein the crosslinker comprises less than 50 wt. % by dry weight of the aqueous binder composition and/or at least 2.5 wt. % by dry weight of the aqueous binder composition.
  • 10. A binder produced by subjecting the aqueous binder composition of claim 1 to drying and optionally curing conditions, wherein the phenalkamine is chemically reacted with the carbohydrate component and/or the crosslinker.
  • 11. A composite product comprising particulate material, fibers and/or sheet material bonded together by the aqueous curable binder composition of claim 10.
  • 12. The composite product of claim 11, wherein the composite product is present in an insulation material comprising mineral fibers.
  • 13. The composite product of claim 11, wherein the composite product is present in a wood particle board, a chip board, a wood fiber board or plywood.
  • 14. A process for manufacturing a composite product comprising providing an assembly of particulate material, chips, fibers, or sheet material, applying the aqueous binder composition of claim 1 to the assembly for forming a resinated material, andsubjecting the resinated material to heat and/or pressure for drying and optionally curing the aqueous curable binder composition.
  • 15. An aqueous binder composition comprising a carbohydrate component, optionally a crosslinker and optionally a reaction product of the carbohydrate component with the crosslinker, and a phenalkamine comprising the general formula
  • 16. The aqueous binder composition of claim 15, wherein the carbohydrate component is selected from the group consisting of monosaccharides, disaccharides, oligosaccharides polysaccharides, in situ precursors thereof and mixtures thereof, the crosslinker is selected from the group consisting of carboxylic acid, salt, ester anhydride derivatives thereof, an ammonium salt of an inorganic acid, a carboxylic acid and a polyamine comprising at least two primary amine functionalities, andwherein the carbohydrate component comprises 30 wt. % by dry weight of the aqueous binder composition to less than 97 wt. % by dry weight of the aqueous binder composition.
Priority Claims (1)
Number Date Country Kind
1610063 Jun 2016 GB national
PCT Information
Filing Document Filing Date Country Kind
PCT/EP2017/063147 5/31/2017 WO 00
Publishing Document Publishing Date Country Kind
WO2017/211642 12/14/2017 WO A
US Referenced Citations (473)
Number Name Date Kind
1801052 Meigs Apr 1931 A
1801053 Meigs Apr 1931 A
1886353 Novotny et al. Nov 1932 A
1902948 Castle Mar 1933 A
1964263 Krenke Jun 1934 A
2198874 Leighton Apr 1940 A
2215825 Wallace et al. Sep 1940 A
2261295 Schlack Nov 1941 A
2362086 Eastes et al. Nov 1944 A
2371990 Hanford Mar 1945 A
2392105 Sussman Jan 1946 A
2442989 Sussman Jun 1948 A
2500665 Courtright Mar 1950 A
2518956 Sussman Aug 1950 A
2875073 Gogek Feb 1959 A
2894920 Ramos Jul 1959 A
2965504 Gogek Dec 1960 A
3038462 Bohdan Jun 1962 A
3138473 Floyd et al. Jun 1964 A
3222243 Gaston et al. Dec 1965 A
3231349 Stalego Jan 1966 A
3232821 Banks et al. Feb 1966 A
3297419 Eyre, Jr. Jan 1967 A
3513001 Woodhead et al. May 1970 A
3551365 Matalon Dec 1970 A
3784408 Jaffe et al. Jan 1974 A
3791807 Etzel et al. Feb 1974 A
3802897 Bovier et al. Apr 1974 A
3809664 Burr et al. May 1974 A
3826767 Hoover et al. Jul 1974 A
3856606 Fan Dec 1974 A
3867119 Takeo et al. Feb 1975 A
3907724 Higginbottom Sep 1975 A
3911048 Nistri et al. Oct 1975 A
3919134 Higginbottom Nov 1975 A
3922466 Bell et al. Nov 1975 A
3955031 Jones et al. May 1976 A
3956204 Higginbottom May 1976 A
3961081 McKenzie Jun 1976 A
3971807 Brack Jul 1976 A
4014726 Fargo Mar 1977 A
4028290 Reid Jun 1977 A
4048127 Gibbons et al. Sep 1977 A
4054713 Sakaguchi et al. Oct 1977 A
4085076 Gibbons et al. Apr 1978 A
4097427 Aitken et al. Jun 1978 A
4107379 Stofko Aug 1978 A
4109057 Nakamura et al. Aug 1978 A
4144027 Habib Mar 1979 A
4148765 Nelson Apr 1979 A
4183997 Stofko Jan 1980 A
4184986 Krasnobajew et al. Jan 1980 A
4186053 Krasnobajew et al. Jan 1980 A
4201247 Shannon May 1980 A
4201857 Krasnobajew et al. May 1980 A
4217414 Walon Aug 1980 A
4233432 Curtis, Jr. Nov 1980 A
4246367 Curtis, Jr. Jan 1981 A
4259190 Fahey Mar 1981 A
4265963 Matalon May 1981 A
4278573 Tessler Jul 1981 A
4296173 Fahey Oct 1981 A
4301310 Wagner Nov 1981 A
4310585 Shannon Jan 1982 A
4322523 Wagner Mar 1982 A
4330443 Rankin May 1982 A
4333484 Keritsis Jun 1982 A
4357194 Stofko Nov 1982 A
4361588 Herz Nov 1982 A
4379101 Smith Apr 1983 A
4393019 Geimer Jul 1983 A
4396430 Matalon Aug 1983 A
4400496 Butler et al. Aug 1983 A
4464523 Neigel et al. Aug 1984 A
4506684 Keritsis Mar 1985 A
4520143 Jellinek May 1985 A
4524164 Viswanathan et al. Jun 1985 A
4631226 Jellinek Dec 1986 A
4654259 Stofko Mar 1987 A
4668716 Pepe et al. May 1987 A
4692478 Viswanathan et al. Sep 1987 A
4714727 Hume, III Dec 1987 A
4720295 Bronshtein Jan 1988 A
4734996 Kim et al. Apr 1988 A
4754056 Ansel et al. Jun 1988 A
4761184 Markessini Aug 1988 A
4780339 Lacourse et al. Oct 1988 A
4828643 Newman et al. May 1989 A
4845162 Schmitt et al. Jul 1989 A
4906237 Johansson et al. Mar 1990 A
4912147 Pfoehler et al. Mar 1990 A
4918861 Carpenter et al. Apr 1990 A
4923980 Blomberg May 1990 A
4950444 Deboufie et al. Aug 1990 A
4988780 Das et al. Jan 1991 A
4992519 Mukherjee Feb 1991 A
5001202 Denis et al. Mar 1991 A
5013405 Izard May 1991 A
5032431 Conner et al. Jul 1991 A
5037930 Shih Aug 1991 A
5041595 Yang et al. Aug 1991 A
5089342 Dhein et al. Feb 1992 A
5095054 Lay et al. Mar 1992 A
5106615 Dikstein Apr 1992 A
5114004 Isono et al. May 1992 A
5123949 Thiessen Jun 1992 A
5124369 Vandichel et al. Jun 1992 A
5128407 Layton et al. Jul 1992 A
5143582 Arkens et al. Sep 1992 A
5151465 Le-Khac Sep 1992 A
5167738 Bichot et al. Dec 1992 A
5198492 Stack Mar 1993 A
5217741 Kawachi et al. Jun 1993 A
5218048 Abe et al. Jun 1993 A
5240498 Matalon et al. Aug 1993 A
5278222 Stack Jan 1994 A
5300144 Adams Apr 1994 A
5300192 Hansen et al. Apr 1994 A
5308896 Hansen et al. May 1994 A
5318990 Strauss Jun 1994 A
5336753 Jung et al. Aug 1994 A
5336755 Pape Aug 1994 A
5336766 Koga et al. Aug 1994 A
5340868 Strauss et al. Aug 1994 A
5352480 Hansen et al. Oct 1994 A
5367849 Bullock Nov 1994 A
5371194 Ferretti Dec 1994 A
5387665 Misawa et al. Feb 1995 A
5389716 Graves Feb 1995 A
5393849 Srinivasan et al. Feb 1995 A
5416139 Zeiszler May 1995 A
5421838 Gosset et al. Jun 1995 A
5424418 Duflot Jun 1995 A
5434233 Kiely et al. Jul 1995 A
5447977 Hansen et al. Sep 1995 A
5470843 Stahl et al. Nov 1995 A
5480973 Goodlad et al. Jan 1996 A
5492756 Seale et al. Feb 1996 A
5498662 Tanaka et al. Mar 1996 A
5503920 Alkire et al. Apr 1996 A
5534612 Taylor et al. Jul 1996 A
5536766 Seyffer et al. Jul 1996 A
5538783 Hansen et al. Jul 1996 A
5543215 Hansen et al. Aug 1996 A
5545279 Hall et al. Aug 1996 A
5547541 Hansen et al. Aug 1996 A
5547745 Hansen et al. Aug 1996 A
5550189 Qin et al. Aug 1996 A
5554730 Woiszwillo et al. Sep 1996 A
5562740 Cook et al. Oct 1996 A
5571618 Hansen et al. Nov 1996 A
5578678 Hartmann et al. Nov 1996 A
5580856 Prestrelski et al. Dec 1996 A
5582682 Ferretti Dec 1996 A
5583193 Aravindakshan et al. Dec 1996 A
5589256 Hansen et al. Dec 1996 A
5589536 Golino et al. Dec 1996 A
5607759 Hansen et al. Mar 1997 A
5608011 Eck et al. Mar 1997 A
5609727 Hansen et al. Mar 1997 A
5614570 Hansen et al. Mar 1997 A
5620940 Birbara et al. Apr 1997 A
5621026 Tanaka et al. Apr 1997 A
5633298 Arfaei et al. May 1997 A
5641561 Hansen et al. Jun 1997 A
5643978 Darwin et al. Jul 1997 A
5645756 Dubin et al. Jul 1997 A
5660904 Andersen et al. Aug 1997 A
5661213 Arkens et al. Aug 1997 A
5670585 Taylor et al. Sep 1997 A
5672418 Hansen et al. Sep 1997 A
5672659 Shalaby et al. Sep 1997 A
5690715 Schiwek Nov 1997 A
5691060 Levy Nov 1997 A
5693411 Hansen et al. Dec 1997 A
5719092 Arrington Feb 1998 A
5719228 Taylor et al. Feb 1998 A
5733624 Syme et al. Mar 1998 A
5756580 Natori et al. May 1998 A
5763524 Arkens et al. Jun 1998 A
5788243 Harshaw et al. Aug 1998 A
5788423 Perkins Aug 1998 A
5807364 Hansen Sep 1998 A
5855987 Margel et al. Jan 1999 A
5863985 Shalaby et al. Jan 1999 A
5885337 Nohr et al. Mar 1999 A
5895804 Lee et al. Apr 1999 A
5905115 Luitjes et al. May 1999 A
5916503 Rettenbacher Jun 1999 A
5919528 Huijs et al. Jul 1999 A
5919831 Philipp Jul 1999 A
5922403 Tecle Jul 1999 A
5925722 Exner et al. Jul 1999 A
5929184 Holmes-Farley et al. Jul 1999 A
5929196 Kissel et al. Jul 1999 A
5932344 Ikemoto et al. Aug 1999 A
5932665 Deporter et al. Aug 1999 A
5932689 Arkens et al. Aug 1999 A
5942123 McArdle Aug 1999 A
5954869 Elfersy et al. Sep 1999 A
5977224 Cheung et al. Nov 1999 A
5977232 Arkens et al. Nov 1999 A
5981719 Woiszwillo et al. Nov 1999 A
5983586 Berdan, II et al. Nov 1999 A
5990216 Cai et al. Nov 1999 A
5993709 Bonomo et al. Nov 1999 A
6022615 Rettenbacher Feb 2000 A
6067821 Jackson et al. May 2000 A
6071549 Hansen Jun 2000 A
6071994 Hummerich et al. Jun 2000 A
6072086 James et al. Jun 2000 A
6077883 Taylor et al. Jun 2000 A
6090925 Woiszwillo et al. Jul 2000 A
6114033 Ikemoto et al. Sep 2000 A
6114464 Reck et al. Sep 2000 A
6133347 Vickers, Jr. et al. Oct 2000 A
6136916 Arkens et al. Oct 2000 A
6139619 Zaretskiy et al. Oct 2000 A
6143243 Gershun et al. Nov 2000 A
6171444 Nigam Jan 2001 B1
6171654 Salsman et al. Jan 2001 B1
6180037 Andersen et al. Jan 2001 B1
6194512 Chen et al. Feb 2001 B1
6210472 Kwan et al. Apr 2001 B1
6221958 Shalaby et al. Apr 2001 B1
6221973 Arkens et al. Apr 2001 B1
6231721 Quick et al. May 2001 B1
6274661 Chen et al. Aug 2001 B1
6281298 Papsin, Jr. Aug 2001 B1
6299677 Johnson et al. Oct 2001 B1
6299936 Reck et al. Oct 2001 B1
6307732 Tsubaki et al. Oct 2001 B1
6310227 Sarama et al. Oct 2001 B1
6313102 Colaco et al. Nov 2001 B1
6319683 James et al. Nov 2001 B1
6331350 Taylor et al. Dec 2001 B1
6331513 Zaid et al. Dec 2001 B1
6340411 Hansen et al. Jan 2002 B1
6348530 Reck et al. Feb 2002 B1
6365079 Winkler et al. Apr 2002 B1
6372077 Tecle Apr 2002 B1
6379739 Formanek et al. Apr 2002 B1
6379814 Dupre et al. Apr 2002 B1
6395856 Petty et al. May 2002 B1
6403665 Sieker et al. Jun 2002 B1
6407225 Mang et al. Jun 2002 B1
6410036 De Rosa et al. Jun 2002 B1
6440204 Rogols et al. Aug 2002 B1
6441122 DeMott et al. Aug 2002 B1
6461553 Hansen et al. Oct 2002 B1
6468442 Bytnar Oct 2002 B2
6468730 Fujiwara et al. Oct 2002 B2
6469120 Elfersy et al. Oct 2002 B1
6475552 Shah et al. Nov 2002 B1
6482875 Lorenz et al. Nov 2002 B2
6495656 Haile et al. Dec 2002 B1
6521339 Hansen et al. Feb 2003 B1
6525009 Sachdev et al. Feb 2003 B2
6538057 Wildburg et al. Mar 2003 B1
6547867 Rogols et al. Apr 2003 B2
6555616 Helbing et al. Apr 2003 B1
6559302 Shah et al. May 2003 B1
6562267 Hansen et al. May 2003 B1
6596103 Hansen et al. Jul 2003 B1
6613378 Erhan et al. Sep 2003 B1
6638882 Helbing et al. Oct 2003 B1
6638884 Quick et al. Oct 2003 B2
6699945 Chen et al. Mar 2004 B1
6706853 Stanssens et al. Mar 2004 B1
6719862 Quick et al. Apr 2004 B2
6730730 Hansen et al. May 2004 B1
6753361 Kroner et al. Jun 2004 B2
6818694 Hindi et al. Nov 2004 B2
6821547 Shah et al. Nov 2004 B2
6852247 Bytnar Feb 2005 B2
6858074 Anderson et al. Feb 2005 B2
6861495 Barsotti et al. Mar 2005 B2
6864044 Ishikawa et al. Mar 2005 B2
6878800 Husemoen et al. Apr 2005 B2
6884849 Chen et al. Apr 2005 B2
6955844 Tagge et al. Oct 2005 B2
6962714 Hei et al. Nov 2005 B2
6989171 Portman Jan 2006 B2
6992203 Trusovs Jan 2006 B2
7018490 Hansen et al. Mar 2006 B2
7029717 Ojima et al. Apr 2006 B1
7067579 Taylor et al. Jun 2006 B2
7083831 Koch et al. Aug 2006 B1
7090745 Beckman et al. Aug 2006 B2
7141626 Rodrigues et al. Nov 2006 B2
7144474 Hansen et al. Dec 2006 B1
7195792 Boston et al. Mar 2007 B2
7201778 Smith et al. Apr 2007 B2
7201825 Dezutter et al. Apr 2007 B2
7202326 Kuroda et al. Apr 2007 B2
7241487 Taylor et al. Jul 2007 B2
7458235 Beaufils et al. Dec 2008 B2
7514027 Horres et al. Apr 2009 B2
7655711 Swift et al. Feb 2010 B2
7772347 Swift et al. Aug 2010 B2
7795354 Srinivasan et al. Sep 2010 B2
7803879 Srinivasan et al. Sep 2010 B2
7807771 Swift et al. Oct 2010 B2
7842382 Helbing Nov 2010 B2
7854980 Jackson et al. Dec 2010 B2
7883693 Sehl et al. Feb 2011 B2
7888445 Swift et al. Feb 2011 B2
7947765 Swift et al. May 2011 B2
8114210 Hampson et al. Feb 2012 B2
8182648 Swift et al. May 2012 B2
8211923 Wagner et al. Jul 2012 B2
8372900 Shooshtari et al. Feb 2013 B2
8377564 Shooshtari et al. Feb 2013 B2
8501838 Jackson et al. Aug 2013 B2
8680224 Zhang et al. Mar 2014 B2
8691934 Helbing et al. Apr 2014 B2
8900495 Pacorel et al. Dec 2014 B2
20010017427 Rosthauser et al. Aug 2001 A1
20010046824 Nigam Nov 2001 A1
20020000100 Burg et al. Jan 2002 A1
20020025435 Hansen et al. Feb 2002 A1
20020026025 Kuo et al. Feb 2002 A1
20020028857 Holy Mar 2002 A1
20020032253 Lorenz et al. Mar 2002 A1
20020042473 Trollsas et al. Apr 2002 A1
20020091185 Taylor et al. Jul 2002 A1
20020096278 Foster et al. Jul 2002 A1
20020123598 Sieker et al. Sep 2002 A1
20020130439 Kroner et al. Sep 2002 A1
20020161108 Schultz et al. Oct 2002 A1
20020197352 Portman Dec 2002 A1
20030005857 Minami et al. Jan 2003 A1
20030040239 Toas et al. Feb 2003 A1
20030044513 Shah et al. Mar 2003 A1
20030066523 Lewis et al. Apr 2003 A1
20030071879 Swenson Apr 2003 A1
20030116294 Kehrer et al. Jun 2003 A1
20030134945 Capps Jul 2003 A1
20030148084 Trocino Aug 2003 A1
20030153690 Husemoen et al. Aug 2003 A1
20030185991 Wigger et al. Oct 2003 A1
20030203117 Bartkowiak et al. Oct 2003 A1
20040002567 Chen et al. Jan 2004 A1
20040019168 Soerens et al. Jan 2004 A1
20040024170 Husemoen et al. Feb 2004 A1
20040033269 Hei et al. Feb 2004 A1
20040033747 Miller et al. Feb 2004 A1
20040034154 Tutin et al. Feb 2004 A1
20040038017 Tutin et al. Feb 2004 A1
20040048531 Belmares et al. Mar 2004 A1
20040077055 Fosdick et al. Apr 2004 A1
20040079499 Dezutter et al. Apr 2004 A1
20040087024 Bellocq et al. May 2004 A1
20040087719 Rautschek et al. May 2004 A1
20040122166 O'Brien-Bernini et al. Jun 2004 A1
20040131874 Tutin et al. Jul 2004 A1
20040144706 Beaufils et al. Jul 2004 A1
20040152824 Dobrowolski Aug 2004 A1
20040161993 Tripp et al. Aug 2004 A1
20040209851 Nelson et al. Oct 2004 A1
20040213930 Halabisky Oct 2004 A1
20040220368 Li et al. Nov 2004 A1
20040249066 Heinzman et al. Dec 2004 A1
20040254285 Rodrigues et al. Dec 2004 A1
20040260082 Van Der Wilden et al. Dec 2004 A1
20050001198 Bytnar Jan 2005 A1
20050017394 Hochsmann Jan 2005 A1
20050027283 Richard et al. Feb 2005 A1
20050033037 Trusovs Feb 2005 A1
20050048212 Clamen et al. Mar 2005 A1
20050059770 Srinivasan et al. Mar 2005 A1
20050171085 Pinto et al. Aug 2005 A1
20050196421 Hunter et al. Sep 2005 A1
20050202224 Helbing Sep 2005 A1
20050208852 Weber Sep 2005 A1
20050215153 Cossement et al. Sep 2005 A1
20050245669 Clungeon et al. Nov 2005 A1
20050275133 Cabell et al. Dec 2005 A1
20050288479 Kuroda et al. Dec 2005 A1
20060005580 Espiard et al. Jan 2006 A1
20060009569 Charbonneau et al. Jan 2006 A1
20060044302 Chen Mar 2006 A1
20060099870 Garcia et al. May 2006 A1
20060111480 Hansen et al. May 2006 A1
20060124538 Morcrette et al. Jun 2006 A1
20060135433 Murray et al. Jun 2006 A1
20060141177 Ligtenberg et al. Jun 2006 A1
20060179892 Horres et al. Aug 2006 A1
20060188465 Perrier et al. Aug 2006 A1
20060198954 Frechem et al. Sep 2006 A1
20060231487 Bartley et al. Oct 2006 A1
20060252855 Pisanova et al. Nov 2006 A1
20060281622 Maricourt et al. Dec 2006 A1
20070006390 Clamen et al. Jan 2007 A1
20070009582 Madsen et al. Jan 2007 A1
20070027281 Michl et al. Feb 2007 A1
20070039520 Crews et al. Feb 2007 A1
20070082983 Crews et al. Apr 2007 A1
20070123679 Swift et al. May 2007 A1
20070123680 Swift et al. May 2007 A1
20070129522 Burckhardt et al. Jun 2007 A1
20070142596 Swift et al. Jun 2007 A1
20070158022 Heep et al. Jul 2007 A1
20070184740 Keller et al. Aug 2007 A1
20070191574 Miller et al. Aug 2007 A1
20070270070 Othman Nov 2007 A1
20070287018 Tutin et al. Dec 2007 A1
20070292618 Srinivasan et al. Dec 2007 A1
20070292619 Srinivasan et al. Dec 2007 A1
20070298274 Eriksson et al. Dec 2007 A1
20080009209 Clamen et al. Jan 2008 A1
20080009616 Frank et al. Jan 2008 A1
20080051539 Kelly Feb 2008 A1
20080060551 Crews et al. Mar 2008 A1
20080081138 Moore et al. Apr 2008 A1
20080108741 Van Herwijnen et al. May 2008 A1
20080160260 Wada et al. Jul 2008 A1
20080160302 Asrar et al. Jul 2008 A1
20080194738 Crews et al. Aug 2008 A1
20090169867 Kelly Jul 2009 A1
20090170978 Kelly Jul 2009 A1
20090227732 Glockner et al. Sep 2009 A1
20090301972 Hines et al. Dec 2009 A1
20090304919 Huenig et al. Dec 2009 A1
20090306255 Patel et al. Dec 2009 A1
20090324915 Swift et al. Dec 2009 A1
20100029160 Srinivasan et al. Feb 2010 A1
20100058661 Jackson et al. Mar 2010 A1
20100080976 Jackson et al. Apr 2010 A1
20100084598 Jackson et al. Apr 2010 A1
20100086726 Jackson et al. Apr 2010 A1
20100087571 Jackson et al. Apr 2010 A1
20100098947 Inoue et al. Apr 2010 A1
20100117023 Dopico et al. May 2010 A1
20100129640 Kelly May 2010 A1
20100130649 Swift et al. May 2010 A1
20100175826 Huenig et al. Jul 2010 A1
20100210595 Wagner et al. Aug 2010 A1
20100222463 Brady et al. Sep 2010 A1
20100222566 Fosdick et al. Sep 2010 A1
20100282996 Jaffrennou et al. Nov 2010 A1
20100301256 Hampson et al. Dec 2010 A1
20100320113 Swift Dec 2010 A1
20110021672 Crews et al. Jan 2011 A1
20110039111 Shooshtari Feb 2011 A1
20110040010 Shooshtari Feb 2011 A1
20110042303 Shooshtari et al. Feb 2011 A1
20110045966 Shooshtari et al. Feb 2011 A1
20110089074 Jackson et al. Apr 2011 A1
20110135937 Swift et al. Jun 2011 A1
20110190425 Swift Aug 2011 A1
20110220835 Swift et al. Sep 2011 A1
20110256790 Toas et al. Oct 2011 A1
20110260094 Hampson et al. Oct 2011 A1
20110262648 Lee et al. Oct 2011 A1
20110263757 Rand et al. Oct 2011 A1
20110306726 Bailey et al. Dec 2011 A1
20120037036 Veit et al. Feb 2012 A1
20120133073 Pacorel et al. May 2012 A1
20120156954 Eckert et al. Jun 2012 A1
20130029150 Appley et al. Jan 2013 A1
20130032749 Jaffrennou et al. Feb 2013 A1
20130047888 Mueller et al. Feb 2013 A1
20130059075 Appley et al. Mar 2013 A1
20130082205 Mueller et al. Apr 2013 A1
20130174758 Mueller Jul 2013 A1
20130234362 Swift et al. Sep 2013 A1
20130236650 Swift et al. Sep 2013 A1
20130237113 Swift et al. Sep 2013 A1
20130244524 Swift et al. Sep 2013 A1
20140091247 Jackson et al. Apr 2014 A1
20140134909 Guo et al. May 2014 A1
20140357787 Jobber et al. Dec 2014 A1
Foreign Referenced Citations (125)
Number Date Country
8538765 Aug 1985 AU
9640921 Jul 1997 AU
1090026 Nov 1980 CA
2037214 Sep 1991 CA
2232334 Nov 1998 CA
2458333 Dec 1999 CA
2278946 Jan 2000 CA
2470783 Dec 2004 CA
1251738 May 2000 CN
1905054 Aug 1969 DE
4142261 Jun 1993 DE
4233622 Apr 1994 DE
4308089 Sep 1994 DE
102004033561 Sep 2005 DE
102005023431 Nov 2006 DE
0044614 Jan 1982 EP
0099801 Feb 1984 EP
354023 Feb 1990 EP
0461995 Dec 1991 EP
0524518 Jan 1993 EP
0547819 Jun 1993 EP
0583086 Feb 1994 EP
0714754 Jun 1996 EP
796681 Sep 1997 EP
0826710 Mar 1998 EP
856494 Aug 1998 EP
0873976 Oct 1998 EP
878135 Nov 1998 EP
0882756 Dec 1998 EP
0911361 Apr 1999 EP
915811 May 1999 EP
936060 Aug 1999 EP
976866 Feb 2000 EP
0990729 Apr 2000 EP
1038433 Sep 2000 EP
1193288 Apr 2002 EP
1084167 Sep 2002 EP
1268702 Jan 2003 EP
1382642 Jan 2004 EP
1486547 Dec 2004 EP
1522642 Apr 2005 EP
1698598 Sep 2006 EP
1767566 Apr 2007 EP
2223940 Sep 2010 EP
2223941 Sep 2010 EP
2253663 Nov 2010 EP
2614388 Oct 1988 FR
770561 Mar 1957 GB
809675 Mar 1959 GB
926749 May 1963 GB
1391172 Apr 1975 GB
1469331 Apr 1977 GB
1512066 May 1978 GB
1525541 Sep 1978 GB
2047258 Nov 1980 GB
2078805 Jan 1982 GB
2173523 Oct 1986 GB
2251438 Jul 1992 GB
53113784 Oct 1978 JP
57101100 Jun 1982 JP
5811193 Jan 1983 JP
61195647 Aug 1986 JP
3-173680 Jul 1991 JP
05186635 Jul 1993 JP
7-034023 Feb 1995 JP
09157627 Jun 1997 JP
10234314 Sep 1998 JP
11035491 Feb 1999 JP
11181690 Jul 1999 JP
2000327841 Nov 2000 JP
2002293576 Sep 2002 JP
2003147276 May 2003 JP
2003238921 Aug 2003 JP
2004060058 Feb 2004 JP
2005306919 Nov 2005 JP
549563 Jan 2008 NZ
1765996 Aug 1995 RU
374400 Mar 1973 SU
1990007541 Jul 1990 WO
1992012198 Jul 1992 WO
1995034517 Dec 1995 WO
1997049646 Dec 1997 WO
1999036368 Jul 1999 WO
199947765 Sep 1999 WO
199960042 Nov 1999 WO
199960043 Nov 1999 WO
200058085 Oct 2000 WO
2001014491 Mar 2001 WO
2001059026 Aug 2001 WO
200200429 Jan 2002 WO
200206178 Jan 2002 WO
2003029496 Apr 2003 WO
2003071879 Sep 2003 WO
2003106561 Dec 2003 WO
2004007615 Jan 2004 WO
2004076734 Sep 2004 WO
2005087837 Sep 2005 WO
2006044302 Apr 2006 WO
2006136614 Dec 2006 WO
2007014236 Feb 2007 WO
2007024020 Mar 2007 WO
2007050964 May 2007 WO
2007112335 Oct 2007 WO
2008089847 Jul 2008 WO
2008089851 Jul 2008 WO
2008141201 Nov 2008 WO
2009019235 Feb 2009 WO
2009129084 Oct 2009 WO
2010027937 Mar 2010 WO
2010139899 Dec 2010 WO
2011019590 Feb 2011 WO
2011019593 Feb 2011 WO
2011019597 Feb 2011 WO
2011019598 Feb 2011 WO
2011022224 Feb 2011 WO
2011022226 Feb 2011 WO
2011022227 Feb 2011 WO
2011091585 Aug 2011 WO
2011138458 Nov 2011 WO
2011138458 Nov 2011 WO
2011138459 Nov 2011 WO
2012152731 Nov 2012 WO
2013030390 Mar 2013 WO
2013150123 Oct 2013 WO
2013159279 Oct 2013 WO
Non-Patent Literature Citations (217)
Entry
International Search Report and Written Opinion for PCT/US2008/059730, completed Sep. 22, 2008.
International Search Report and Written Opinion for PCT/US2008/069046, completed Sep. 25, 2008.
International Search Report and Written Opinion for PCT/EP2011/059317, completed Jul. 15, 2011.
International Search Report for PCT/EP2008/060185, completed Oct. 23, 2008.
International Search Report for PCT/EP2011/057363, completed Sep. 5, 2011.
Ames, J.M., “The Maillard Browning Reaction—an Update, ”Chemistry & Industry, No. 17, 1988, 4 pages.
“Gamma-aminopropyltrimethoxysilane,” Hawley's Condensed Chemical Dictionary, 14th Edition, John Wiley & Sons, Inc., 2002, 1 page.
Hodge, J.E., Chemistry of Browning Reactions in Model Systems, 1953, J. Agric. Food Chem., vol. 1, No. 15, pp. 928-943.
Agyei-Aye et al., “The Role of Anion in the Reaction of Reducing Sugars with Ammonium Salts,” Carbohydrate Research 2002, 337: 2273-2277.
Laroque et al., “Kinetic study on the Maillard reaction. Consideration of sugar reactivity,” Food Chemistry 2008, 111: 1032-1042.
Bjorksten et al., “Polyester Resin—Glass Fiber Laminates,” Industrial and Engineering Chemistry (1954).
Dow Corning, “A Guide to Silane Solutions,” 2005.
Knauf Data Sheet, 2006.
Molasses Corporation, United States Sugar Corporation, http://www.suga-lik.com/molasses/composition.html (Sep. 29, 2003).
Clamen, Guy, “Acrylic Thermosets: A Safe Alternative to Formaldehyde Resins,” Nonwovens World, Apr.-May 2004, pp. 96-102.
Opposition to AU 2006272595, Amended Statement of Grounds and Particulars, issued from Australian Patent Office, Jul. 6, 2012, 22 pages.
Decision re Opposition to AU 2006272595, issued from Australian Patent Office, Aug. 14, 2015, 25 pages.
Opposition to EP 1732968, Notice of Opposition: Prior Art, Scope of the Patent, Reasons for the Opposition, issued from European Patent Office, Mar. 8, 2012, 18 pages.
Decision re Opposition to EP 1732968, issued from the European Patent Office, Nov. 14, 2014, 5 pages.
Opposition to EA 019802, submitted to Eurasian Patent Office on Dec. 26, 2014, 36 pages.
Decision re Opposition to EA 019802, issued by Eurasian Patent Office on Aug. 18, 2015, 15 pages.
Owens Corning Retiree Update: What Goes Around, Comes Around: A tale of Natural Binders, revised Mar. 20, 2013 p. 4.
A.P. Bryant, “The Terminology of Sugars,” Industrial and Engineering Chemistry, vol. 26, No. 2, p. 231, Feb. 1934.
Food Flavor Chemistry, p. 162, Mar. 21, 2009 (English Abstract).
Viswanathan, T., “Chapter 28: Thermosetting Adhesive Resins from Whey and Whey Byproducts,” in Adhesives from Renewable Resources, ACS Symposium Series, Hemingway, R.W., et al. (Eds.), American Chemical Society, Washington, DC (1989).
Viswanathan, T., and Richardson, T., “Thermosetting Adhesive Resins from Whey and Whey Byproducts,” Ind. Eng. Chem. Prod. Res. Dev. 23:644-47, American Chemical Society, United States (1984).
Residential Energy Conservation: vol. 1, Congress of the U.S., Office of Technology Assessment (Ed.), 357 pages (Jan. 1, 1979).
Office action for co-pending U.S. Appl. No. 12/524,502 (9 pages)—dated Sep. 21, 2012.
Office action for co-pending U.S. Appl. No. 12/524,502 (9 pages)—dated Apr. 4, 2013.
Office action for co-pending U.S. Appl. No. 12/524,512 (7 pages)—dated Aug. 6, 2012.
Office action for co-pending U.S. Appl. No. 12/524,512 (9 pages)—dated Apr. 1, 2013.
Office action for co-pending U.S. Appl. No. 12/524,512 (14 pages)—dated Nov. 12, 2014.
Office action for co-pending U.S. Appl. No. 12/524,512 (9 pages)—dated Jul. 10, 2015.
Office action for co-pending U.S. Appl. No. 12/524,512 (10 pages)—dated Mar. 23, 2016.
Office action for co-pending U.S. Appl. No. 12/524,512 (13 pages)—dated Oct. 5, 2016.
Office action for co-pending U.S. Appl. No. 12/524,512 (13 pages)—dated Apr. 6, 2018.
Office action for co-pending US Appl. No. 12/524,512 (15 pages)—dated Jan. 17, 2019.
Office action for co-pending U.S. Appl. No. 12/524,469 (7 pages)—dated Jun. 7, 2012.
Office action for co-pending U.S. Appl. No. 12/524,469 (8 pages)—dated Jan. 29, 2013.
Office action for co-pending U.S. Appl. No. 12/524,469 (7 pages)—dated Aug. 20, 2013.
Office action for co-pending U.S. Appl. No. 12/524,469 (9 pages)—dated Jun. 9, 2014.
Office action for co-pending U.S. Appl. No. 12/524,469 (9 pages)—dated Oct. 17, 2014.
Office action for co-pending U.S. Appl. No. 12/524,469 (9 pages)—dated Jul. 23, 2015.
Office action for co-pending U.S. Appl. No. 12/524,539 (13 pages)—dated Jun. 21, 2012.
Office action for co-pending U.S. Appl. No. 12/524,539 (13 pages)—dated Jun. 6, 2013.
Office action for co-pending U.S. Appl. No. 12/524,539 (12 pages)—dated Dec. 17, 2014.
Office action for co-pending U.S. Appl. No. 12/524,539 (7 pages)—dated Jul. 15, 2015.
Office action for co-pending U.S. Appl. No. 12/524,539 (7 pages)—dated Mar. 23, 2016.
Office action for co-pending U.S. Appl. No. 12/524,539 (7 pages)—dated Dec. 29, 2016.
Office action for co-pending U.S. Appl. No. 12/524,522 (4 pages)—dated Oct. 11, 2011.
Office action for co-pending U.S. Appl. No. 12/667,718 (5 pages)—dated Sep. 3, 2013.
Office action for co-pending U.S. Appl. No. 12/667,718 (6 pages)—dated Sep. 9, 2014.
Office action for co-pending U.S. Appl. No. 12/671,922 (10 pages)—dated Oct. 7, 2011.
Office action for co-pending U.S. Appl. No. 12/671,922 (10 pages)—dated May 10, 2012.
Office action for co-pending U.S. Appl. No. 12/671,922 (9 pages)—dated Sep. 23, 2014.
Office action for co-pending U.S. Appl. No. 12/671,922 (5 pages)—dated Apr. 4, 2016.
Office action for co-pending U.S. Appl. No. 13/388,408 (5 pages)—dated Aug. 15, 2013.
Office action for co-pending U.S. Appl. No. 13/371,829 (9 pages)—dated Dec. 20, 2012.
Office action for co-pending U.S. Appl. No. 13/371,829 (6 pages)—dated Jul. 12, 2013.
Office action for co-pending U.S. Appl. No. 13/371,829 (6 pages)—dated Aug. 12, 2014.
Office action for co-pending U.S. Appl. No. 13/637,794 (8 pages)—dated Aug. 12, 2013.
Office action for co-pending U.S. Appl. No. 13/637,794 (9 pages)—dated Mar. 26, 2014.
Office action for co-pending U.S. Appl. No. 13/696,439 (11 pages)—dated Jan. 8, 2014.
Office action for co-pending U.S. Appl. No. 13/696,452 (7 pages)—dated Jan. 13, 2015.
Office action for co-pending U.S. Appl. No. 13/696,452 (9 pages)—dated Oct. 27, 2015.
Office action for co-pending U.S. Appl. No. 13/702,144 (6 pages)—dated Jan. 10, 2014.
Office action for co-pending U.S. Appl. No. 13/702,144 (7 pages)—dated Jul. 29, 2014.
Office action for co-pending U.S. Appl. No. 13/823,818 (9 pages)—dated Mar. 26, 2015.
Office action for co-pending U.S. Appl. No. 13/866,368 (16 pages)—dated Aug. 29, 2013.
Office action for co-pending U.S. Appl. No. 13/866,368 (11 pages)—dated Apr. 16, 2014.
Office action for co-pending U.S. Appl. No. 13/866,368 (8 pages)—dated Aug. 21, 2014.
Office action for co-pending U.S. Appl. No. 13/866,419 (14 pages)—dated Sep. 20, 2013.
Office action for co-pending U.S. Appl. No. 13/866,419 (10 pages)—dated Apr. 25, 2014.
Office action for co-pending U.S. Appl. No. 13/866,419 (8 pages)—dated Oct. 9, 2014.
Office action for co-pending U.S. Appl. No. 13/866,419 (8 pages)—dated Sep. 25, 2015.
Office action for co-pending U.S. Appl. No. 13/868,233 (23 pages)—dated Aug. 13, 2013.
Office action for co-pending U.S. Appl. No. 13/868,233 (12 pages)—dated Apr. 15, 2014.
Office action for co-pending U.S. Appl. No. 13/868,233 (8 pages)—dated Oct. 7, 2014.
Office action for co-pending U.S. Appl. No. 13/868,233 (8 pages)—dated Jul. 16, 2015.
Office action for co-pending U.S. Appl. No. 13/868,238 (8 pages)—dated Jul. 16, 2014.
Office action for co-pending U.S. Appl. No. 12/976,379 (7 pages)—dated Jan. 10, 2012.
Office action for co-pending U.S. Appl. No. 12/976,379 (6 pages)—dated Jul. 27, 2012.
Office action for co-pending U.S. Appl. No. 12/976,379 (9 pages)—dated Mar. 7, 2013.
Office action for co-pending U.S. Appl. No. 12/976,379 (8 pages)—dated Aug. 20, 2013.
Office action for co-pending U.S. Appl. No. 12/599,858 (8 pages)—dated May 11, 2011.
Office action for co-pending U.S. Appl. No. 13/341,542 (8 pages)—dated Dec. 26, 2012.
Office action for co-pending U.S. Appl. No. 13/341,542 (7 pages)—dated Feb. 10, 2014.
Office action for co-pending U.S. Appl. No. 14/026,394 (6 pages)—dated Aug. 14, 2014.
Office action for co-pending U.S. Appl. No. 14/272,556 (14 pages)—dated Nov. 20,2014.
Office action for co-pending U.S. Appl. No. 14/272,556 (12 pages)—dated Sep. 17, 2015.
Office action for co-pending U.S. Appl. No. 14/342,069 (17 pages)—dated Dec. 29, 2015.
Office action for co-pending U.S. Appl. No. 14/342,069 (22 pages)—dated Sep. 2, 2016.
Office action for co-pending U.S. Appl. No. 14/342,069 (21 pages)—dated Sep. 26, 2017.
Office action for co-pending U.S. Appl. No. 14/342,069 (21 pages)—dated Jun. 6, 2018.
Office action for co-pending U.S. Appl. No. 14/649,277 (9 pages)—dated Jul. 22, 2016.
Office action for co-pending U.S. Appl. No. 14/686,915 (8 pages)—dated Nov. 18, 2016.
Office action for co-pending U.S. Appl. No. 14/810,765 (7 pages)—dated Jan. 29, 2016.
Office action for co-pending U.S. Appl. No. 14/828,916 (8 pages)—dated Nov. 25, 2016.
Office action for co-pending U.S. Appl. No. 14/867,502 (9 pages)—dated Nov. 18, 2016.
Office action for co-pending U.S. Appl. No. 15/172,432 (16 pages)—dated Apr. 17, 2017.
Office action for co-pending U.S. Appl. No. 15/702,087 (5 pages)—dated Nov. 9, 2018.
Office action for co-pending U.S. Appl. No. 15/177,442 (17 pages)—dated May 19, 2017.
Office action for co-pending U.S. Appl. No. 15/378,159 (18 pages)—dated Mar. 2, 2017.
Office action for co-pending U.S. Appl. No. 15/222,122 (8 pages)—dated Nov. 20, 2017.
Office action for co-pending U.S. Appl. No. 15/310,837 (13 pages)—dated Jun. 21, 2018.
Office action for co-pending U.S. Appl. No. 15/411,972 (9 pages)—dated Mar. 28, 2017.
Office action for co-pending U.S. Appl. No. 15/411,972 (8 pages)—dated Nov. 29, 2017.
Office action for co-pending U.S. Appl. No. 15/411,972 (9 pages)—dated Jun. 14, 2018.
Office action for co-pending U.S. Appl. No. 15/116,254 (8 pages)—dated Apr. 26, 2018.
Office action for co-pending U.S. Appl. No. 15/116,254 (10 pages)—dated Aug. 15, 2018.
Office action for co-pending U.S. Appl. No. 15/333,670 (5 pages)—dated Dec. 8, 2017.
Office Action for co-pending U.S. Appl. No. 14/116,048 (10 pages)—dated Jun. 23, 2017.
Office action for co-pending U.S. Appl. No. 15/959,131 (8 pages)—dated Nov. 8, 2019.
Office action for co-pending U.S. Appl. No. 15/822,102 (6 pages)—dated Dec. 6, 2019.
Office action for co-pending U.S. Appl. No. 15/690,623 (6 pages)—dated Jan. 9, 2020.
Other Information—Narrative of verbal disclosure of Brian Swift (1 page)—May 13, 2014.
Petition for Inter Partes Review of U.S. Pat. No. 8,114,210 (52 pages, filed Jun. 12, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 8,114,210 (58 pages, filed Jun. 12, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with Petition for Inter Partes Review of U.S. Pat. No. 8,114,210).
1st Petition for Inter Partes Review of U.S. Pat. No. D. 631,670 (68 pages, filed Jun. 19, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
2nd Petition for Inter Partes Review of U.S. Pat. No. D. 631,670 (62 pages, filed Nov. 2, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Decision of PTAB regarding Institution of Inter Partes Review for U.S. Pat. No. D. 631,670 (33 pages)—Jan. 12, 2016.
Decision2 of PTAB regarding Institution of Inter Partes Review for U.S. Pat. No. D. 631,670 (27 pages)—May 9, 2016.
Final Written Decision of PTAB regarding Inter Partes Review of U.S. Pat. No. D. 631,670 based on 1st Petition (56 pages)—Jan. 11, 2017.
Final Written Decision of PTAB regarding Inter Partes Review of U.S. Pat. No. D. 631,670 based on 2nd Petition (55 pages)—May 8, 2017.
Court of Appeals for Federal Circuit Judgment from Appeal of PTAB Decisions in Inter Partes Reviews of U.S. Pat. No. D. 631,670 (2 pages)—Jul. 13, 2018.
1st Petition for Inter Partes Review of U.S. Pat. No. 8,940,089 (61 pages, filed Jul. 1, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 8,940,089 (70 pages, filed Jul. 1, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. In connection with 1st Petition for Inter Partes Review of U.S. Pat. No. 8,940,089).
2nd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089 (56 pages, filed Jul. 10, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 8,940,089 (67 pages, filed Jul. 10, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 2nd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089).
3rd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089 (62 pages, filed Jul. 17, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 8,940,089 (76 pages, filed Jul. 17, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 3rd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089).
Declaration of Dr. Elam Leed (11 pages, filed Jul. 1, Jul. 10, and Jul. 17, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st, 2nd and 3rd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089, respectively).
Declaration of Dr. Jonathan Vickers (10 pages, filed Jul. 1, Jul. 10, and Jul. 17, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st, 2nd and 3rd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089, respectively).
1st Petition for Inter Partes Review of U.S. Pat. No. 9,039,827 (60 pages, filed Jul. 29, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 9,039,827 (72 pages, filed Jul. 29, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st Petition for Inter Partes Review of U.S. Pat. No. 9,039,827).
2nd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827 (51 pages, filed Aug. 5, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 9,039,827 (65 pages, filed Aug. 5, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 2nd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827).
3rd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827 (57 pages, filed Aug. 7, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 9,039,827 (75 pages, filed Aug. 7, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 3rd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827).
Declaration of Dr. Elam Leed (11 pages, filed Jul. 29, Aug. 5, and Aug. 7, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st, 2nd and 3rd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827, respectively).
Declaration of Dr. Jonathan Vickers (10 pages, filed Jul. 29, Aug. 5, and Aug. 7, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st, 2nd and 3rd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827, respectively).
Petition for Inter Partes Review of U.S. Pat. No. 9,469,747 (67 pages, filed Mar. 20, 2018 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Petition for Inter Partes Review of U.S. Pat. No. 9,828,287 (86 pages, filed Mar. 23, 2018 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Petition for Inter Partes Review of U.S. Pat. No. 9,464,207 (78 pages, filed Mar. 28, 2018 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Petition for Inter Partes Review of U.S. Pat. No. 9,926,464 (74 pages, filed Mar. 30, 2018 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Office Action Granting Ex Parte Reexamination of U.S. Pat. No. 7,888,445, dated Dec. 24, 2013, in Control No. 90/013,029, 11 pages.
Office Action Granting Ex Parte Reexamination of U.S. Pat. No. 7,772,347, dated Dec. 24, 2013, in Control No. 90/013,030, 14 pages.
Office Action Granting Ex Parte Reexamination of U.S. Pat. No. 7,854,980, dated Apr. 15, 2014, in Control No. 90/013,156, 20 pages.
Declaration of Jan Rud Andersen submitted in Ex parte Reexamination Control No. 90/013,030, as Document OTH-C, Oct. 10, 2013, 4 pages.
Final Rejection in Ex Parte Reexamination of U.S. Pat. No. 7,888,445 (20 pages)—Jul. 24, 2015.
Final Rejection in Ex Parte Reexamination of U.S. Pat. No. 7,772,347 (23 pages)—Jul. 24, 2015.
Final Rejection in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (31 pages)—Aug. 18, 2015.
Advisory Action in Ex Parte Reexamination of U.S. Pat. No. 7,888,445 (4 pages)—Oct. 6, 2015.
Advisory Action in Ex Parte Reexamination of U.S. Pat. No. 7,772,347 (4 pages)—Oct. 6, 2015.
Advisory Action in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (4 pages)—Nov. 18, 2015.
Examiner's Answer in Ex Parte Reexamination of U.S. Pat. No. 7,888,445 (8 pages)—Mar. 23, 2016.
Examiner's Answer in Ex Parte Reexamination of U.S. Pat. No. 7,772,347 (8 pages)—Mar. 23, 2016.
Examiner's Answer in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (8 pages)—Mar. 22, 2016.
Decision of PTAB in Ex Parte Reexamination of U.S. Pat. No. 7,888,445 (17 pages)—Sep. 29, 2016.
Decision of PTAB in Ex Parte Reexamination of U.S. Pat. No. 7,772,347 (18 pages)—Sep. 29, 2016.
Decision of PTAB in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (22 pages)—Sep. 30, 2016.
Court of Appeals for Federal Circuit Judgment from Consolidated Appeal of PTAB Decisions in Ex Parte Reexamination of U.S. Pat. Nos. 7,888,445, 7,772,347 and 7,854,980 (5 pages)—Mar. 9, 2018.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 7,772,347 (4 pages)—Oct. 24, 2018.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 7,888,445 (4 pages)—Dec. 7, 2018.
Notice of Intent to Issue Inter Partes Reexamination Certificate for U.S. Pat. No. 7,888,445 (14 pages)—Sep. 24, 2020.
Notice of Intent to Issue Inter Partes Reexamination Certificate for U.S. Pat. No. 7,772,347 (13 pages)—Sep. 25, 2020.
Decision of USPTO to Reopen Prosecution in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (7 pages)—Jan. 7, 2019.
Non-final Office Action from Reopened Prosecution in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (26 pages)—dated Apr. 3, 2019.
Final Office Action from Reopened Prosecution in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (11 pages)—dated Aug. 8, 2019.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 7,854,980 (3 pages)—Oct. 29, 2019.
Notice of Intent to Issue Inter Partes Reexamination Certificate for U.S. Pat. No. 7,807,771 (4 pages)—Jan. 30, 2014.
Notice of Intent to Issue Inter Partes Reexamination Certificate for U.S. Pat. No. 7,854,980 (6 pages)—Aug. 31, 2017.
Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (34 pages)—May 1, 2015.
Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (36 pages)—May 1, 2015.
Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,854,980 (25 pages)—Jul. 30, 2015.
Remand Order of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (5 pages)—Dec. 9, 2015.
Remand Order of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (5 pages)—Dec. 9 , 2015.
Examiner's Determination on Patent Owner Response/Requester Comments after Board Decision in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (22 pages)—Oct. 17, 2016.
Examiner's Determination on Patent Owner Response/Requester Comments after Board Decision in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (17 pages)—Oct. 17, 2016.
Court of Appeals for Federal Circuit Opinion/Judgment from Appeal of PTAB Decision in Inter Partes Reexamination of U.S. Pat. No. 7,854,980 (13 pages)—Feb. 27, 2017.
Final Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (25 pages)—Sep. 8, 2017.
Final Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (24 pages)—Sep. 8, 2017.
Decision of PTAB re Request for Rehearing in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (7 pages)—Feb. 12, 2018.
Decision of PTAB re Request for Rehearing in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (7 pages)—Feb. 12, 2018.
Court of Appeals for Federal Circuit Decision re Consolidated Appeal of PTAB Decision in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 and U.S. Pat. No. 7,888,445 (14 pages)—Oct. 15, 2019.
Remand Order of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (3 pages)—Jul. 1, 2020.
Remand Order of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (3 pages)—Jul. 1, 2020.
Decision of PTAB regarding Institution of Inter Partes Review for U.S. Pat. No. 8,114,210 (20 pages)—Oct. 21, 2015.
Final Written Decision of PTAB regarding Inter Partes Review of U.S. Pat. No. 8,114,210 (39 pages)—Oct. 19, 2016.
Court of Appeals for Federal Circuit Judgment from Appeal of PTAB Decision in Inter Partes Review of U.S. Pat. No. 8,114,210 (5 pages)—Jan. 16, 2018.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 8,114,210 (11 pages)—Apr. 9, 2020.
Decision1 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 8,940,089 (16 pages)—Dec. 17, 2015.
Decision2 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 8,940,089 (19 paages)—Dec. 17, 2015.
Decision3 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 8,940,089 (14 pages)—Dec. 17, 2015.
Decision1 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 9,039,827 (16 pages)—Jan. 4, 2016.
Decision2 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 9,039,827 (19 pages)—Jan. 4, 2016.
Decision3 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 9,039,827 (14 pages)—Jan. 4, 2016.
Decision of PTAB denying Institution of Inter Partes Review for U.S. Pat. No. 9,926,464 (29 pages)—Oct. 2, 2018.
Decision of PTAB denying Institution of Inter Partes Review for U.S. Pat. No. 9,464,207 (28 pages)—Oct. 2, 2018.
Decision of PTAB denying Institution of Inter Partes Review for U.S. Pat. No. 9,469,747 (29 pages)—Oct. 3, 2018.
Decision of PTAB denying Institution of Inter Partes Review for U.S. Pat. No. 9,828,287 (22 pages)—Oct. 16, 2018.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,828,287 (13 pages)—Jul. 17, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,464,207 (14 pages)—Jul. 31, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,926,464 (18 pages)—Aug. 5, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 8,940,089 (17 pages)—Oct. 16, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,039,827 (16 pages)—Oct. 16, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,469,747 (16 pages)—Nov. 9, 2020.
Statement of Revocation Grounds re GB2496951—Claimant Rockwool International (May 21, 2018, 22 pages).
Statement of Revocation Grounds re GB2451719—Claimant Rockwool International (May 18, 2018, 22 pages).
Expert Report re Revocation of GB2451719 and GB2496951—Claimant Rockwool International (Nov. 12, 2018, 11 pages).
United Kingdom Intellectual Property Office, Decision in Rockwool International v. Knauf Insulation Limited, Application under Section 72 for revocation of patents GB2451719 and GB2496951 (May 28, 2019—18 pages).
Decision of EPO Board of Appeal re Added Matter vis-à-vis EP06788492.4 (Jul. 17, 2019—14 pages).
U.S. Pat. No. 2,965,504—Part 1 (10 pages).
U.S. Pat. No. 2,965,504—Part 2 (14 pages).
U.S. Pat. No. 2,965,504—Part 3 (14 pages).
Gogek Attorney Comments re U.S. Pat. No. 2,965,504—Apr. 6, 1960 (3 pages).
Gogek Affidavit Under Rule 132 re U.S. Pat. No. 2,965,504—Feb. 26, 1960 (3 pages).
Related Publications (1)
Number Date Country
20190257078 A1 Aug 2019 US